Neurophysiological Characteristics in Type II and Type III 5q Spinal Muscular Atrophy Patients: Impact of Nusinersen Treatment
Dan Li,Na Sun,Li Xiang,Jingjie Liu,Xueying Wang,Lin Yang,Shaoping Huang
DOI: https://doi.org/10.2147/dddt.s449066
IF: 4.3188
2024-03-28
Drug Design Development and Therapy
Abstract:Dan Li, 1, &ast Na Sun, 1, &ast Li Xiang, 2 Jingjie Liu, 2 Xueying Wang, 1 Lin Yang, 1, &ast Shaoping Huang 1, &ast 1 Department of Pediatrics, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China; 2 Department of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shaoping Huang; Lin Yang, Department of Pediatrics, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an, Shaanxi, 710004, People's Republic of China, Tel +86-18681852505, Email ; Objective: This study aimed to observe the neurophysiological characteristics of type II and type III 5q spinal muscular atrophy (SMA) patients and the changes in peripheral motor nerve electrophysiology after Nusinersen treatment, as well as the influencing factors. Methods: This single-center retrospective case–control study collected clinical data and peripheral motor nerve CMAP parameters from 42 5qSMA patients and 42 healthy controls at the Second Affiliated Hospital of Xi'an Jiaotong University (January 2021 to December 2022). It evaluated changes in motor function and CMAP amplitude before and after Nusinersen treatment. Results: Our investigation encompassed all symptomatic and genetically confirmed SMA patients, consisting of 32 type II and 10 type III cases, with a median age of 57 months (29.5 to 96 months). Comparative analysis with healthy controls revealed substantial reductions in CMAP amplitudes across various nerves in both type II and type III patients. Despite the administration of Nusinersen treatment for 6 or 14 months to the entire cohort, discernible alterations in motor nerve amplitudes were not observed, except for a significant improvement in younger patients (≤ 36 months) at the 14-month mark. Further scrutiny within the type II subgroup unveiled that individuals with a disease duration ≤ 12 months experienced a noteworthy upswing in femoral nerve amplitude, a statistically significant difference when compared to those with > 12 months of disease duration. Conclusion: Motor nerve amplitudes were significantly decreased in type II and type III 5q SMA patients compared to healthy controls. Nusinersen treatment showed better improvement in motor nerve amplitudes in younger age groups and those with shorter disease duration, indicating a treatment-time dependence. Keywords: 5q spinal muscular atrophy, neurophysiology, peripheral motor nerve, Nusinersen Spinal muscular atrophy (SMA) is a rare autosomal recessive genetic disorder. Deletion or mutation of the SMN1 gene on chromosome 5q13.2 has been identified as the most common cause of reduced full-length functional SMN protein, and it is the predominant subtype of SMA, accounting for the majority of cases. 1 SMA is characterized by progressive muscle atrophy and weakness due to the loss of motor neurons in the spinal anterior horn. A large-scale study found that carriers of SMN1 gene deletion have a frequency of 1/54 in the population, with an incidence rate of 1/11,000. 2–4 Based on the age of onset and the timing of milestone motor events, five types (0 to IV) have been established. Prenatal onset type 0 and infantile onset type I are the most severe and associated with increased mortality. Historically, SMA has been a major cause of monogenic infant mortality. 5,6 However, with the widespread use of gene-modifying therapies, this is expected to change significantly. Previous meta-analyses have found significant differences in compound muscle action potential (CMAP) and motor unit number index (MUNIX) as neurophysiological biomarkers between SMA patients and healthy controls, specifically in the distal muscles of the upper limbs. 7 However, the placement of muscle electrodes in pediatric patients may cause pain and psychological fear, and the inability to cooperate in muscle contractions makes MUNIX examination difficult to perform. On the other hand, CMAP measurements are more feasible due to their good repeatability and non-invasive nature, making them more readily accepted by both patients and parents. CMAP has been shown to be strongly correlated with clinical classification, age, and SMN2 gene copy number in SMA. 8 In type I patients, CMAP amplitudes were found to be significantly low (mean 0.340 mV), well below the lower limit of normal (1.80 mV). 9 Additionally, another study reported significantly reduced CMAP amplitudes in 10 type II SMA patients compared to the normal values. 10 P -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal